Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2022-11-23 Regulatory Filings
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions an 'Other Events' section describing a press release about FDA approval of a product, and includes the press release as an exhibit. There are no financial statements or detailed financial data presented. The document length is 3327 characters, which is relatively short and primarily serves as an announcement of an event rather than a detailed financial or management report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-11-23 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 2, 2022, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2022. The text explicitly states that the press release is furnished as an exhibit to the Form 8-K and is a current report on Form 8-K. The document length is 4003 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the full financial results or detailed analysis itself. According to the classification rules, such a document announcing quarterly financial results in a Form 8-K format is best classified as an Earnings Release (ER).
2022-11-02 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-02 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-10-07 English
AMENDMENT TO FORM SC 13G
Major Shareholding Notification
2022-09-26 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-23 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.